ACNS1723: A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)
What is the goal of the study?
This study will investigate if a combination of these two MAPK pathway inhibitors (dabrafenib and trametinib) will improve event-free survival (EFS) in children with newly-diagnosed BRAFV600-mutant HGG. Patients will undergo a maximal safe surgical resection and tumor tissue will be sent for rapid central screening coordinated by the Biopathology Center, including histopathologic review and molecular sequencing to confirm the presence of a BRAFV600 mutation. Eligible patients who consent to this trial will receive standardized local irradiation (target dose of 5459.4 Gy) followed by maintenance cycles of dabrafenib and trametinib. Patients will receive up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity.
Who can participate in the study?
Please contact the study team listed below to learn more.